Innovaderm Bolsters European Presence With The Addition of Operational Capabilities in Poland and Spain
MONTREAL, QUEBEC, July 28, 2022 – Innovaderm announced today that its strategic European expansion initiative has reached a major milestone with the addition of operational capabilities in Poland and Spain.
Biotechnology and pharmaceutical companies can officially partner with the CRO’s team of experts to manage clinical trials in psoriasis, acne, atopic dermatitis and other dermatology indications in Europe. This includes adherence to stringent regulatory requirements, patient recruitment, site selection, clinical monitoring and protocol writing.
“To date, we have successfully completed more than 500 clinical trials at 2,900 sites,” says Dave Selkirk, Innovaderm’s Chief Operating Officer. “The expansion of our services in Europe will allow us to go one step further and accelerate the development of promising therapies that have the potential to transform lives. As we look to the future, our goal is to continue supporting innovation in research and the increasing number of patients with skin conditions worldwide.”
“These are exciting times for Innovaderm,” adds Anne Marie Gaulin, Chief Business Officer. “Our highly skilled employees are specialized in dermatology and understand the nuances of deep regional and pan-European requirements. With its site network, medical expertise, and established KOL relationships, Innovaderm is ready to help customers advance the next generation of dermatology treatments.”
Innovaderm is one of the largest, independent, full-service CROs in the field of dermatology with early to late phase clinical trial capabilities in 30+ indications. To learn more, click here.